Description: Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Home Page: www.novartis.com
Lichtstrasse 35
Basel,
4056
Switzerland
Phone:
41 61 324 1111
Officers
| Name | Title |
|---|---|
| Dr. Vasant Narasimhan | Chief Exec. Officer |
| Mr. Harry Kirsch | Chief Financial Officer |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer |
| Ms. Karen L. Hale | Chief Legal Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer |
| Mr. Steffen Lang Ph.D. | Pres of Operations |
| Ms. Marie-France Tschudin | Pres of Innovative Medicines International & Chief Commercial Officer |
| Mr. Richard Saynor | Chief Exec. Officer of Sandoz |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Dr. Samir Shah M.D. | Global Head of Investor Relations |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 14.4509 |
|---|---|
| Trailing PE: | 9.3062 |
| Price-to-Book MRQ: | 3.2548 |
| Price-to-Sales TTM: | 3.4827 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 108000 |